Rocket Pharmaceuticals, Inc. (RCKT) stock
Close on Nov 17, 2026Market cap $231.62MP/E –Yield –
Rocket Pharmaceuticals, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. Free cash flow was -$170.39M. At the latest close the market valued the company at $231.62M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $231.62M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.63
- Dividend yield
- –
- Free cash flow yield
- -73.56%
Fundamentals
- Revenue
- $0
- Net income
- -$17.25M
- EPS, diluted
- -$0.17
- Free cash flow
- -$170.39M
- Book value per share
- $3.22
- Diluted shares
- 115M
Trading
- Next earnings
- Feb 25, 2027 (estimated, after the close)
- Previous close
- $2.16
- Open
- $2.16
- Day's range
- $2.03 – $2.19
- Volume
- 1,785,209
- Average volume (20 days)
- 1,645,095
- Index membership
- Russell 2000, Russell 3000
- 52-week range
- $2.15 – $5.45
- RSI (14 days)
- 37.0
- Volatility (1 year)
- 68.7%
- Relative volume
- 1.11×
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | RCKT | S&P 500 | Difference | RCKT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.2% | -4.0% | +0.8 pts | ||
| 3 months | -37.9% | -5.0% | −33.0 pts | ||
| Year to date | -39.9% | +8.2% | −48.1 pts | ||
| 1 year | -30.6% | +11.2% | −41.8 pts | ||
| 3 years | -90.4% | +68.5% | −158.9 pts | -54.2% | +19.0% |
| 5 years | -92.2% | +67.3% | −159.4 pts | -39.9% | +10.8% |
| 10 years | -91.9% | +291.6% | −383.5 pts | -22.2% | +14.6% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Rocket Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Update
About Rocket Pharmaceuticals
Pharmaceutical Preparations
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing gene therapies for rare and life-threatening diseases. The company develops treatments using adeno-associated virus and lentiviral vector platforms to target conditions such as Danon disease, Fanconi anemia, pyruvate kinase deficiency, leukocyte adhesion deficiency-I, and cardiomyopathies. Its primary customers and end users include patients afflicted with severe genetic disorders, alongside the physicians, healthcare providers, and clinical institutions that treat these conditions.
Company profile, executives and historyRocket Pharmaceuticals stock: common questions
What is Rocket Pharmaceuticals's stock price?
RCKT closed at $2.11 on Nov 17, 2026, down 2.31% on the day. Over the past 52 weeks it traded between $2.15 and $5.45.
What is Rocket Pharmaceuticals's market cap?
Rocket Pharmaceuticals was worth $231.62M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is RCKT's P/E ratio?
Rocket Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.17), so it has no meaningful P/E ratio.
How much revenue does Rocket Pharmaceuticals make?
Rocket Pharmaceuticals reported revenue of $0 for the twelve months to Jun 30, 2026.
Does Rocket Pharmaceuticals pay a dividend?
No. Rocket Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Rocket Pharmaceuticals report earnings next?
Rocket Pharmaceuticals is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has RCKT stock performed over the past year?
Including dividends, RCKT returned -30.6% over the past year, against +11.2% for the S&P 500.
How many RCKT shares are sold short?
16M shares were sold short at the latest FINRA report, 19.05% of the float, or 9.1 days of average trading volume.
Who are Rocket Pharmaceuticals's competitors?
Companies most similar to Rocket Pharmaceuticals by business, industry and size include SNGX, GRCE, RKTO, ABEO, NGNE.
See a number that looks wrong?